ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
13.29
-0.15 (-1.12%)
At close: May 12, 2025, 4:00 PM
14.00
+0.71 (5.34%)
After-hours: May 12, 2025, 7:28 PM EDT
ARS Pharmaceuticals Revenue
In the year 2024, ARS Pharmaceuticals had annual revenue of $89.15M with 297,063.33% growth. ARS Pharmaceuticals had revenue of $86.58M in the quarter ending December 31, 2024.
Revenue (ttm)
$89.15M
Revenue Growth
+297,063.33%
P/S Ratio
14.45
Revenue / Employee
$557,181
Employees
160
Market Cap
1.31B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
Dec 31, 2020 | 17.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SPRY News
- 5 days ago - ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - GlobeNewsWire
- 7 days ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - GlobeNewsWire
- 10 days ago - ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewsWire
- 12 days ago - ARS Pharmaceuticals Has A Blockbuster Candidate - Seeking Alpha
- 7 weeks ago - ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await - Seeking Alpha
- 7 weeks ago - ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 7 weeks ago - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - GlobeNewsWire